Whether sparsentan (sparsentan) needs to be taken continuously and the discontinuation plan

Sparsentan (Sparsentan) is an oral dual angiotensin receptor-endothelin receptor antagonist (ARB-ERA). It is mainly used to treat patients with primary immunoglobulin A nephropathy (IgAN). It can effectively reduce proteinuria and delay the decline of renal function. Since its main mechanism of action is long-term regulation of angiotensin and endothelin signaling pathways, the efficacy of the drug is closely related to continued use. Therefore, in clinical practice, it is usually recommended that patients take the drug long-term and regularly to maintain the therapeutic effect.

Most patients will need to continue taking sparsentane to maintain proteinuria reduction and renal protection. Discontinuation of the drug may result in rebound proteinuria or accelerated decline in renal function. Therefore, unless serious adverse reactions occur or the doctor assesses that the patient has reached a stable long-term remission state, it is generally not recommended to discontinue the medication on your own. The safety of long-term medication has been shown to be good in clinical trials, but blood pressure, electrolytes and renal function indicators still need to be monitored regularly.

If the medication needs to be stopped, it must be done under the guidance of a professional doctor. Before discontinuing medication, doctors typically evaluate patients' blood pressure control, renal function, proteinuria levels, and other comorbidities. For some patients, gradual dose reduction and observation can be considered to reduce the impact on renal function and the risk of proteinuria rebound. During the withdrawal process, clinical symptoms, such as edema, abnormal blood pressure, or increased urine protein, should be paid close attention to, and treatment should be resumed or the plan adjusted immediately if necessary.

After discontinuation of medication, patients still need to undergo close follow-up and regular laboratory monitoring, including blood pressure, serum creatinine, urine protein, blood electrolytes and other indicators. It is recommended to review every 1 to 2 weeks in the initial stage. After stabilization, the review can be extended to monthly or quarterly. If abnormal indicators are found during monitoring, the drug should be resumed promptly or alternative treatment should be adopted. In addition, patients should maintain a healthy lifestyle during drug withdrawal, including a low-salt diet, regular exercise, and weight control to support stable renal function. Through scientific drug withdrawal management and regular monitoring, risks can be reduced and treatment strategies can be safely adjusted when necessary.

Reference materials:https://www.drugs.com/